Systemic management of adrenal malignancies: adrenocortical carcinoma and pheochromocytoma/paraganglioma
Endocrine Connections · 01.07.2026 · 15 (7)
DOI: 10.1530/ec-26-0334 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Connections, online erschienen am 14.07.2026. Verfasst von Jorge H Hernandez-Felix und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán , Mexico City, Mexico. Die Arbeit nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Adrenal malignancies include adrenocortical carcinoma (ACC) and pheochromocytoma/paraganglioma (PPGL), rare endocrine tumors that share an adrenal or extra-adrenal location but differ substantially in origin, hormonal activity, molecular alterations, metastatic potential, and systemic treatment. In ACC, management is guided by stage, resectability, Ki-67, hormone secretion, tumor volume, and pace of progression. Mitotane remains the central ACC-specific therapy, used according to recurrence risk after surgery and as monotherapy in selected patients with advanced, low-volume disease. When rapid tumor control is needed, etoposide, doxorubicin, cisplatin, and mitotane remain the standard first-line regimen. Immune checkpoint inhibitors and multikinase inhibitors have shown activity in some patients, but validated predictive biomarkers are lacking, and access across Europe is limited by reimbursement differences. In later lines, chemotherapy may still be appropriate, including platinum rechallenge in selected cases. PPGL care is increasingly driven by genetics, biochemistry, and functional imaging. Germline testing, biochemical phenotype, and imaging findings are essential for risk assessment and treatment choice. Cyclophosphamide, vincristine, and dacarbazine may be considered for aggressive disease, rapid growth, or high tumor burden. Targeted and radiopharmaceutical approaches have expanded options, including high-specific-activity 131I-iobenguane for MIBG-avid tumors, 177Lu-DOTATATE for somatostatin receptor-positive disease, antiangiogenic tyrosine kinase inhibitors, and HIF-2α inhibition with belzutifan in selected molecular contexts. For both ACC and PPGL, controlling steroid or catecholamine excess is crucial because endocrine complications affect treatment tolerance and outcomes. Future progress requires robust biomarkers, rational treatment sequencing, and trials using disease-specific endpoints beyond radiographic response and integrating patient-centered endocrine, molecular, and overall clinical measures of benefit.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán , Mexico City, Mexico.
- Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia at ASST Spedali Civili di Brescia , Brescia, Italy.
- Division of Internal Medicine 2, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili , Brescia, Italy.
- Developmental Therapeutics Branch, National Cancer Institute/National Institutes of Health , Bethesda, Maryland, USA.
ORCID-Profile: Jorge H Hernandez-Felix
Zitieren
APA
Hernandez-Felix, J. H., Lagana, M., Cosentini, D., Tacchetti, M. C., Berruti, A., & Del Rivero, J. (2026). Systemic management of adrenal malignancies: adrenocortical carcinoma and pheochromocytoma/paraganglioma. Endocrine Connections, 15(7). https://doi.org/10.1530/ec-26-0334
Vancouver
Hernandez-Felix JH, Lagana M, Cosentini D, Tacchetti MC, Berruti A, Del Rivero J. Systemic management of adrenal malignancies: adrenocortical carcinoma and pheochromocytoma/paraganglioma. Endocrine Connections. 2026;15(7). doi:10.1530/ec-26-0334
BibTeX
@article{HernandezFelix2026,
author = {Hernandez-Felix, Jorge H and Lagana, Marta and Cosentini, Deborah and Tacchetti, Maria Chiara and Berruti, Alfredo and Del Rivero, Jaydira},
title = {Systemic management of adrenal malignancies: adrenocortical carcinoma and pheochromocytoma/paraganglioma},
journal = {Endocrine Connections},
year = {2026},
volume = {15},
number = {7},
doi = {10.1530/ec-26-0334}
}
EUVIMED